Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Conditions
Interventions
Ixekizumab
Placebo
Locations
99
United States
Arizona Arthritis Research, PLC
Phoenix, Arizona, United States
Rheumatology Center of San Diego
Escondido, California, United States
Care Access Research - Huntington Beach
Huntington Beach, California, United States
Desert Medical Advances
Palm Desert, California, United States
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
Colorado Springs, Colorado, United States
Denver Arthritis Center
Denver, Colorado, United States
Start Date
April 12, 2016
Primary Completion Date
May 18, 2018
Completion Date
May 3, 2019
Last Updated
June 17, 2020
NCT06888193
NCT06707194
NCT06988813
NCT06222671
NCT05676775
NCT07460739
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions